Curia Appoints Steve Lavezoli as Vice President, Biologics
Curia Receives 2024 CDMO Leadership Award
Curia Appoints Gerald Auer as Chief Financial Officer
ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in...
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
Albany, NY and Hampton, UK – July 24, 2023 – Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA). The arrangement expands Curia’s mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers. Under the arrangement, Touchlight will directly manufacture dbDNA on behalf of Curia’s customers.
ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value...
Curia Expands Cell Line Development Offering with CHOZN Platform
Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs
Curia Appoints Philip Macnabb as Chief Executive Officer